jRCT2051230018招募中不适用
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements (FOENIX-CCA4)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 13
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •A patient must meet all of the following inclusion criteria to be eligible for participation in this study:
- •Histologically or cytologically confirmed, locally advanced, metastatic, unresectable iCCA or eCCA who had documented evidence of FGFR2 gene fusions or other rearrangements using next generation sequencing (NGS) or fluorescence in situ hybridization (FISH)
- •Received at least one prior systemic gemcitabine and platinum-based regimen for CCA.
- •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009)
- •Documentation of radiographic disease progression on the most recent prior therapy
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Adequate organ function
排除标准
- •A patient must not meet any of the following exclusion criteria to be eligible for participation in this study:
- •History or current evidence of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (except commonly observed calcifications in soft tissues such as the skin, kidney, tendons, or vessels due to injury, disease, and aging in the absence of systemic mineral imbalance)
- •Current evidence of clinically significant retinal disorder as confirmed by ophthalmological examination
- •Treatment with any of the following within the specified time frame prior to the first dose of futibatinib:
- •Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of futibatinib)
- •Radiotherapy for extended field within 4 weeks or limited field radiotherapy within 2 weeks
- •Patients with locoregional therapy, eg, transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) or ablation within 4 weeks
- •Any noninvestigational anticancer therapy within 3 weeks or have not recovered from side effects of such therapy prior to futibatinib administration (mitomycin within prior 5 weeks). Endocrine therapy is allowed for patients with breast or prostate cancer
- •Targeted therapy or immunotherapy within 3 weeks or within 5 half lives (whichever is shorter)
- •Any investigational agent received within 5 half-lives of the drug or 4 weeks, whichever is shorter. Concurrent participation in an observational study may be allowed after review by the Sponsor's Medical Monitor.
- •Patients with prior FGFR-directed therapy
- •A serious illness or medical condition(s) including (but not limited to) the following:
- •Known brain metastasis unless patient is clinically stable for >= 1 month
- •Known acute systemic infection
- •Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure; if >2 months, cardiac function must be within normal limits and the patient must be free of cardiac-related symptoms
- •Significant gastrointestinal disorder(s) that could interfere with the absorption of futibatinib
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the Investigator would make the patient inappropriate for entry into this study
- •Known additional malignancy that is progressing or requires active treatment, with the exception of patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or antitumor assessment of the investigational regimen.
- •Exceptions must be discussed with the Sponsor prior to patient enrollment.
- •Pregnant or lactating female
- •Known hypersensitivity or severe reaction to futibatinib or its excipients
结局指标
主要结局
Overall Response Rate (ORR)
by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by BICR
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16
招募中
不适用
Phase 2 study of afatinib in patients with previously treated advanced non-sq NSCLC haboring EGFR mutatioJPRN-UMIN000014981Gunma University Graduate School of Medicine55
已完成
2 期
Afatinib in pretreated patients with advanced NSCLC harbouring HER2 exon 20 mutationsadvanced non-small cell lung cancer1003866610029107NL-OMON42560European Thoracic Oncology Platform (ETOP)6
进行中（未招募）
1 期
Trial to evaluatie the ability of afatinib to control disease in patients with advanced non-small cell lung cancer harboring a specific gene mutation (change) in the human epidermal growth factor 2 (HER 2)Advanced stage NSCLC, harbouring HER2 exon 20 mutationsMedDRA version: 18.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005098-35-DEETOP (European Thoracic Oncology Platform)22
进行中（未招募）
1 期
Trial to evaluate the ability of afatinib to control disease in patients with advanced non-small cell lung cancer harbouring a specific gene mutation (change) in the human epidermal growth factor 2 (HER 2)Advanced stage NSCLC, harbouring HER2 exon 20 mutationsMedDRA version: 18.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005098-35-NLETOP (European Thoracic Oncology Platform)22